Robust data from population- and genetic-based studies support the causal relationship of serum cholesterol and blood pressure levels with atherosclerotic cardiovascular disease (ASCVD) events.1 High-quality randomized trials have demonstrated the independent benefits of cholesterol and blood pressure lowering in reducing incident and recurrent ASCVD events with commonly used and low-cost medicines, including statins and blood pressure–lowering drugs.2,3 Despite evidence and endorsement of simultaneously targeting multiple risk factors for the prevention of ASCVD events, the specific approach of using fixed-dose combinations of cholesterol- and blood pressure–lowering drugs (and aspirin in the context of secondary prevention), also known as polypills, remains limited.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Huffman MD, Salam A, Patel A. Implementation Strategies for Cardiovascular Polypills. JAMA. 2019;322(23):2279–2280. doi:10.1001/jama.2019.18102
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: